- Human pathology

Home > A. Molecular pathology > Targeted therapy > Therapeutical antibodies > brodalumab


Tuesday 10 May 2016


Brodalumab binds to the interleukin-17 receptor (IL17R) and so prevents interleukin 17 (IL-17) from activating the receptor. This mechanism is similar to that of another anti-psoriasis antibody, ixekizumab, which however binds to IL-17 itself.

Brodalumab was developed by Amgen, Inc. In 2013, it was in two phase III clinical trials for the treatment of moderate to severe psoriasis.